Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib for High-Risk AML Post-Transplant
NCT01841333Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Apr 2013
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glasdegib in acute myeloid leukemia (AML), sponsored by University of Colorado Denver. Started Apr 2013; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01841333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01841333.